NVCR · NovoCure Ltd · Documents
$13.15
+0.04 (+0.31%)
At close · Oct 30
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Market Cap
$1.54B
Shares
116.92M
Volume · Oct 30
1.97M
Avg daily vol (3M)
1.44M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | — | 2026-10-29 | — | |
| 10-Q | — | 2026-10-29 | 2026-09-30 | |
| 8-K | Japan’s Ministry of Health, Labour and Welfare approved Novocure’s Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. | 2026-10-01 | — | |
| Investor Event Transcript | — | 2026-09-09 | 2026-09-30 | |
| 8-K | — | 2026-09-09 | 2026-09-02 | |
| 8-K | — | 2026-09-01 | — | |
| 10-Q | — | 2026-07-23 | 2026-06-30 | |
| 8-K | — | 2026-07-23 | — | |
| 8-K | — | 2026-06-30 | — | |
| 8-K | — | 2026-06-18 | — | |
| 8-K | — | 2026-06-05 | 2026-06-03 | |
| DEFA14A | — | 2026-05-21 | — | |
| 8-K | — | 2026-04-30 | — | |
| 10-Q | — | 2026-04-30 | 2026-03-31 | |
| 8-K/A | — | 2026-04-24 | 2025-11-24 | |
| DEFA14A | — | 2026-04-20 | — | |
| DEF 14A | — | 2026-04-20 | 2026-06-03 | |
| 8-K | — | 2026-04-09 | 2026-04-08 | |
| 8-K | — | 2026-03-26 | — | |
| 10-K | — | 2026-02-26 | 2025-12-31 | |
| 8-K | — | 2026-02-26 | — | |
| 8-K | — | 2026-02-24 | — | |
| 8-K | — | 2026-02-11 | — | |
| 8-K | — | 2026-02-05 | 2026-01-30 | |
| 8-K | — | 2026-01-12 | — | |
| 8-K | — | 2025-12-01 | 2025-11-24 | |
| 8-K | — | 2025-10-30 | — | |
| 10-Q | — | 2025-10-30 | 2025-09-30 | |
| 8-K | — | 2025-09-15 | — | |
| 8-K | — | 2025-08-28 | — | |
| 10-Q | — | 2025-07-24 | 2025-06-30 | |
| 8-K | — | 2025-07-24 | — | |
| 8-K | — | 2025-06-06 | 2025-06-04 | |
| 8-K | — | 2025-06-02 | 2025-05-31 | |
| 8-K | — | 2025-04-24 | — | |
| 10-Q | — | 2025-04-24 | 2025-03-31 | |
| 8-K | — | 2025-04-22 | — | |
| DEFA14A | — | 2025-04-21 | — | |
| DEF 14A | — | 2025-04-21 | 2025-06-04 | |
| 8-K | — | 2025-02-27 | — | |
| 10-K | — | 2025-02-27 | 2024-12-31 | |
| 8-K | — | 2025-01-13 | — | |
| 8-K/A | — | 2024-12-17 | 2024-08-30 | |
| 8-K | — | 2024-12-02 | — | |
| 10-Q | — | 2024-10-30 | 2024-09-30 | |
| 8-K | — | 2024-10-30 | 2024-10-29 | |
| 8-K | — | 2024-10-15 | — | |
| 8-K | — | 2024-09-03 | 2024-08-30 | |
| 8-K | — | 2024-07-25 | — | |
| 10-Q | — | 2024-07-25 | 2024-06-30 |
Showing 1–50 of 144 filings
Key facts
CIK
1645113
CUSIP
G6674U108
13F (30d)
60 filings
52 filers
Visit website
Investor relations